Atreca Inc BCEL

Alternate Symbol(s): COLUF

Atreca, Inc. is a clinical-stage biopharmaceutical company. The Company is discovering and developing antibody-based therapeutics to treat a range of solid tumor types. Its most advanced product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. It commenced clinical development of ATRC-101 with a Phase Ib clinical trial evaluating ATRC-101 as a monotherapy in patients with select solid tumors and opens a new cohort to evaluate ATRC-101 in combination with pembrolizumab, a PD-1 checkpoint inhibitor. It is also advancing additional product candidates using its discovery platform. Its oncology programs include APN-497444, an ADC against a tumor glycan target, and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target.

PINL:BCEL - Post by User

Atreca Inc

Bullboard Posts

Comment by sweatmanon May 28, 2013 11:47pm

175 Views

Post# 21454004

RE: RE: RE: RE: RE: RE: RE: RE: RE: RE: RE: Instit

Excellent. I never mind being put on ignore by the company touts, as they usually have nothing special to add to the narrative at the best of times. I will continue to pick an entry price that is lower than the current price....and do appreciate the tremendous mopping up program that is taking place with this one. 15 million shares traded over the last few days and the share price is holding. One can only wonder when the shock and awe program will seriously get going. To be safe, it still might be a good idea to make sure the new mining laws will come down exactly as promised, what?

Bullboard Posts

Morning Market Outlook for May 6, 2024